TM
ADPT icon

Triatomic Management’s Adaptive Biotechnologies ADPT Stock Holding History

Triatomic Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,000
Closed -$353K – 53
2023
Q1 		$353K Sell
40,000
-40,000
-50% -$353K 0.24% 43
2022
Q4 		$611K Buy
+80,000
New +$622K 0.51% 27

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Triatomic Management's ADPT Position: Q2 2024 in Review

Triatomic Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2024, closing a stake of 98,555 shares — an estimated $316K sold.

Triatomic Management first reported a position in ADPT in Q4 2021 and held it in 10 quarters. The position peaked at $4.12M in Q1 2022. 176 funds tracked by Wall St. Rank hold ADPT as of Q2 2024.

  • Triatomic Management reported no remaining Adaptive Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Triatomic Management sold 98,555 Adaptive Biotechnologies shares in Q2 2024, an estimated $316K.
  • Triatomic Management first reported a position in Adaptive Biotechnologies in Q4 2021 and held it in 10 quarters.
  • Triatomic Management's Adaptive Biotechnologies position peaked at $4.12M in Q1 2022.
  • 176 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2024.

Based on Triatomic Management's 13F filing for Q2 2024, filed 14 Aug 2024.